{"url_path":"/sec/derm/8-k/2026-06-26/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-077888-index.html","accession_number":"0001104659-26-077888","cik":"0001867066","ticker":"DERM","issuer_name":"Journey Medical Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-077888-index.html","primary_entity_key":"0001867066","primary_entity_name":"Journey Medical Corp"},"word_count":440,"has_tables":true,"body_markdown":"**Item 5.07.**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 24, 2026, Journey Medical Corporation\n(the “Company”) held its 2026 Annual Meeting at 11:00 a.m. Eastern Time by means of an online virtual meeting platform.\nStockholders representing 16,145,526 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company\nand 6,000,000 shares of the Company’s Class A Common Stock of the Company, par value $0.0001 per share, or together 81% of\nthe 27,346,466 shares entitled to vote, were represented in person or by proxy, constituting a quorum.\n\n \n\nAt the 2026 Annual Meeting, the following two\nproposals were approved: (i) the election of six directors to hold office until the 2027 annual meeting of stockholders or until\ntheir successors are duly elected and qualified; and (ii) the ratification of the appointment of KPMG LLP as the Company’s\nindependent registered public accounting firm for the year ending December 31, 2026. The two proposals are described in detail in\nthe Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the SEC on April 30, 2026.\n\n \n\nAs of the April 28, 2026 record date for\nthe determination of the stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting, 21,346,466 shares of the Company’s\nCommon Stock were outstanding and eligible to vote with an aggregate of 21,346,466 votes, and 6,000,000 shares of the Company’s\nClass A Common Stock, each such share of Class A Common Stock entitled to 3.91 votes per share, were outstanding and eligible\nto vote with an aggregate of 23,481,091 votes, as determined in accordance with Article IV, Section 3.2 of the Company’s\nThird Amended and Restated Certificate of Incorporation.\n\n \n\n**Proposal 1**\n\n \n\nThe votes with respect to the election of six\ndirectors to hold office until the 2027 annual meeting of stockholders were as follows:\n\n \n\n**Director**\n \n**Votes For**\n \n**Votes\nWithheld**\n \n**Broker Non-Votes**\n\nLindsay A. Rosenwald, M.D.\n \n32,559,583\n \n551,063\n \n6,515,971\n\nClaude Maraoui\n \n32,972,638\n \n138,008\n \n6,515,971\n\nNeil Herskowitz\n \n31,728,709\n \n1,381,937\n \n6,515,971\n\nJustin Smith\n \n32,873,028\n \n237,618\n \n6,515,971\n\nMiranda Toledano\n \n32,513,215\n \n597,431\n \n6,515,971\n\nMichael Pearce\n \n32,972,865\n \n137,781\n \n6,515,971\n\n \n\n**Proposal 2**\n\n \n\nThe vote with respect to the ratification of KPMG\nLLP as the Company’s independent registered accounting firm for the year ending December 31, 2026 was as follows:\n\n \n\n**Total Votes For**\n \n**Total Votes Against**\n \n**Abstentions**\n\n39,374,407\n \n50,168\n \n202,042\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\n \n**Journey Medical Corporation**\n\n \n \n\n \n(Registrant)\n\n \n \n\nDate: June 25, 2026\n \n\n \nBy:\n/s/ Claude Maraoui\n\n \n \nClaude Maraoui\n\n \n \nChief Executive Officer, President and Director"}